09:56 AM EST - Fennec Pharmaceuticals Inc. : Reported financial results for the third quarter ended September 30, 2018. Cash and cash equivalents were $24.5 million as of September 30, 2018. The Company had a working capital balance of $22.9 million as of September 30, 2018. Research and development (R&D) expenses were $1.8 million for the quarter, compared to $0.5 million for the same period in 2017. Net loss was $2.7 million and $2.4 million for the three months ended September 30, 2018 and 2017, respectively. Fennec Pharmaceuticals Inc.
shares T.FRX are trading up $0.23 at $9.61.
